> Details

Ceccon, G. [Author]; Lohmann, Philipp [Author]; Shah, N. J. [Author]; Fink, Gereon Rudolf [Author]; Langen, Karl-Josef [Author]; Galldiks, Norbert [Author]; Werner, Jan-Michael [Author]; Caroline, Tscherpel [Author]; Dunkl, Veronika [Author]; Stoffels, Gabriele [Author]; Rosen, Jurij [Author]; Rapp, Marion [Author]; Herrlinger, Ulrich [Author]; Schäfer, Niklas [Author]

Early treatment response assessment using $^{18}$F-FET PET compared to contrast-enhanced MRI in glioma patients after adjuvant temozolomide chemotherapy

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Early treatment response assessment using $^{18}$F-FET PET compared to contrast-enhanced MRI in glioma patients after adjuvant temozolomide chemotherapy
  • Contributor: Ceccon, G. [Author]; Lohmann, Philipp [Author]; Shah, N. J. [Author]; Fink, Gereon Rudolf [Author]; Langen, Karl-Josef [Author]; Galldiks, Norbert [Author]; Werner, Jan-Michael [Author]; Caroline, Tscherpel [Author]; Dunkl, Veronika [Author]; Stoffels, Gabriele [Author]; Rosen, Jurij [Author]; Rapp, Marion [Author]; Herrlinger, Ulrich [Author]; Schäfer, Niklas [Author]
  • Published: Soc., 2021
  • Published in: Journal of nuclear medicine 62(7), 918-925 (2021). doi:10.2967/jnumed.120.254243
  • Language: English
  • DOI: https://doi.org/10.2967/jnumed.120.254243
  • ISSN: 0022-3123
  • Origination:
  • Footnote: Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
  • Description: The goal of this study was to compare the value of contrast-enhanced MRI and O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) PET for response assessment in glioma patients after adjuvant temozolomide chemotherapy (TMZ). Methods: After biopsy or resection and completion of radiotherapy with concomitant TMZ, 41 newly diagnosed and histomolecularly characterized glioma patients (glioblastoma, 90%; age range, 20–79 y) were subsequently treated with adjuvant TMZ. MR and 18F-FET PET imaging were performed at baseline and after the second cycle of adjuvant TMZ. We obtained 18F-FET metabolic tumor volumes (MTVs) as well as mean and maximum tumor-to-brain ratios (TBRmean and TBRmax, respectively). Threshold values of 18F-FET PET parameters to predict outcome were established by receiver-operating-characteristic analyses using a median progression-free survival (PFS) of ≥ 9 mo and overall survival (OS) of ≥ 15 mo as reference. MRI response assessment was based on the Response Assessment in Neuro-Oncology (RANO) working group criteria. The predictive value of changes of 18F-FET PET and MRI parameters on survival was evaluated subsequently using univariate and multivariate survival estimates. Results: After 2 cycles of adjuvant TMZ chemotherapy, a treatment-induced reduction of MTV and TBRmax predicted a significantly longer PFS and OS (both P ≤ 0.03; univariate survival analyses) whereas RANO criteria were not significant (P > 0.05). Multivariate survival analysis revealed that TBRmax changes predicted a prolonged PFS (P = 0.012) and changes of MTV a prolonged OS (P = 0.005) independent of O6-methylguanine-DNA-methyltransferase promoter methylation and other strong prognostic factors. Conclusion: Changes of 18F-FET PET parameters appear to be helpful for identifying responders to adjuvant TMZ early after treatment initiation.
  • Access State: Open Access